Full Press Release Details
promising anti tumor activity of novel costimulatory bispecific antibody regn7075 egfrxcd28 in combination with libtayo cemiplimab to be reported at asco.
REGN
promising anti tumor activity of novel costimulatory bispecific antibody regn7075 egfrxcd28 in combination with libtayo cemiplimab to be reported at asco
Key Takeaway: promising anti tumor activity of novel costimulatory bispecific antibody regn7075 egfrxcd28 in combination with libtayo cemiplimab to be reported at asco